The strong feasibility data and initiation of the pivotal trial suggest potential for nPulse to become a best-in-class AF treatment. Traders should monitor enrollment progress and upcoming clinical milestones as potential catalysts, especially given the technology's advantages in procedure efficiency and safety profile.
Price Chart
Executive Summary
Pulse Biosciences announced the first patient enrollment in its NANOPULSE-AF pivotal clinical study, evaluating its nPulse Cardiac Catheter System for treating atrial fibrillation. The trial follows strong feasibility results showing 96% procedural success at 12 months.
Key Facts
- First patients enrolled in the NANOPULSE-AF IDE pivotal clinical study
- Study aims to enroll approximately 215 participants across up to 30 U.S. and European centers
- Prior feasibility study showed 96% procedural success at 12 months and 100% acute success
- n Pulse System integrates with Abbott's EnSite X mapping system for enhanced visualization
- Trial evaluates safety and effectiveness of nanosecond pulsed field ablation (nsPFA) for drug-resistant paroxysmal AF
Financial Impact
No immediate financial impact disclosed, but successful trial outcomes could significantly expand market opportunity in the $2B+ cardiac ablation market
Risk Factors
- Clinical trial may not replicate feasibility results in larger, multicenter setting
- Regulatory approval not guaranteed despite promising early data
- Competition from established AF ablation technologies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-011546 |
| Exhibit: ex_942349.htm | 0001437749-26-011546 |
| Document: 0001437749-26-011546-index-headers.html | 0001437749-26-011546 |
| Document: 0001437749-26-011546-index.html | 0001437749-26-011546 |
| Document: 0001437749-26-011546.txt | 0001437749-26-011546 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $46.32 | awaiting T+60 | — | $52.66 (+13.69%) |
Oct 7, 2026 19d ago | 8-K | $49.09 | awaiting T+60 | — | $52.66 (+7.27%) |
Sep 15, 2026 5w ago | 8-K | $55.20 | awaiting T+60 | — | $52.66 (−4.60%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $52.66 (+53.75%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $52.66 (+116.09%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $52.66 (+110.72%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $52.66 (+105.62%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $52.66 (+176.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers